Stanley Druckenmiller Protagonist Therapeutics, Inc Transaction History
Duquesne Family Office LLC
- $4.06 Billion
- Q3 2025
A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Duquesne Family Office LLC holds 159,700 shares of PTGX stock, worth $13.5 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
159,700Holding current value
$13.5 Million% of portfolio
0.26%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
296Shares Held
66.9MCall Options Held
139KPut Options Held
40.7K-
Farallon Capital Management LLC San Francisco, CA6.2MShares$524 Million1.78% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$487 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$487 Million5.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$360 Million0.0% of portfolio
-
State Street Corp Boston, MA3.17MShares$268 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $4.15B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...